High-Risk Prostate Cancer and Radiotherapy: The Past and the Future. A Benchmark for a New Mixed Beam Radiotherapy Approach

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Radiotherapy still remains a fundamental approach in the treatment of prostate cancer even in high-risk patients. In the past decade, dose escalation has guaranteed a better local control of disease with a great tolerance in terms of side effects. Our results constitute a benchmarking exercise for a prospective trial that involves the use of heavy particles as integration of conventional treatment with photons. Background The prognosis for patients with high-risk prostate cancer is poor. No consensus exists on the most effective treatment. The aim of this retrospective study was to identify the biochemical progression-free survival and the toxicity profile of patients with localized high-risk prostate cancer treated with external beam radiation therapy. These results will constitute a benchmark for a prospective “mixed beam” trial: a boost with carbon ions followed by a pelvic photon intensity-modulated radiotherapy (NCT02672449 [clinicaltrials.gov]). Patients and Methods We retrospectively reviewed the data of 76 patients treated in our institution with photon radiation therapy according to the inclusion criteria of the future “mixed beam” trial: cT3a and/or serum prostate-specific antigen > 20 ng/mL and/or Gleason score of 8 to 10, cN0 cM0. Toxicity, and biochemical and clinical progression-free survival were assessed. Results Seventy-six patients fulfilled our criteria. The median follow-up was 30.2 months (range, 7.2-61.1). Biochemical progression was observed in 22 patients (28.9%) after a median time of 20.2 months (range, 5-58.1) from the end of radiotherapy. Sixteen patients had clinical progression, in all the cases preceded by biochemical progression. Fifty-seven patients (75%) are alive with no evidence of disease, 13 (17.1%) are alive with clinically evident disease, 6 died (3 of prostate disease 3.9%). Conclusion Our results suggest that a more aggressive treatment is necessary. Local treatment intensification based on the “mixed beam” approach combining carbon ions (with its known radiobiological advantages) and photons might represent a promising strategy in high-risk prostate cancer and it will be investigated with our prospective clinical trial.

Original languageEnglish
Pages (from-to)376-383
Number of pages8
JournalClinical Genitourinary Cancer
Volume15
Issue number3
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Benchmarking
Prostatic Neoplasms
Radiotherapy
Photons
Disease-Free Survival
Carbon
Ions
Therapeutics
Intensity-Modulated Radiotherapy
Neoplasm Grading
Prostate-Specific Antigen
Prostate
Retrospective Studies
Clinical Trials
Exercise

Keywords

  • Carbon ions
  • Mix beam approach
  • Photons
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

@article{c0ac9c6d8fb346cea735e76072d4dd6e,
title = "High-Risk Prostate Cancer and Radiotherapy: The Past and the Future. A Benchmark for a New Mixed Beam Radiotherapy Approach",
abstract = "Radiotherapy still remains a fundamental approach in the treatment of prostate cancer even in high-risk patients. In the past decade, dose escalation has guaranteed a better local control of disease with a great tolerance in terms of side effects. Our results constitute a benchmarking exercise for a prospective trial that involves the use of heavy particles as integration of conventional treatment with photons. Background The prognosis for patients with high-risk prostate cancer is poor. No consensus exists on the most effective treatment. The aim of this retrospective study was to identify the biochemical progression-free survival and the toxicity profile of patients with localized high-risk prostate cancer treated with external beam radiation therapy. These results will constitute a benchmark for a prospective “mixed beam” trial: a boost with carbon ions followed by a pelvic photon intensity-modulated radiotherapy (NCT02672449 [clinicaltrials.gov]). Patients and Methods We retrospectively reviewed the data of 76 patients treated in our institution with photon radiation therapy according to the inclusion criteria of the future “mixed beam” trial: cT3a and/or serum prostate-specific antigen > 20 ng/mL and/or Gleason score of 8 to 10, cN0 cM0. Toxicity, and biochemical and clinical progression-free survival were assessed. Results Seventy-six patients fulfilled our criteria. The median follow-up was 30.2 months (range, 7.2-61.1). Biochemical progression was observed in 22 patients (28.9{\%}) after a median time of 20.2 months (range, 5-58.1) from the end of radiotherapy. Sixteen patients had clinical progression, in all the cases preceded by biochemical progression. Fifty-seven patients (75{\%}) are alive with no evidence of disease, 13 (17.1{\%}) are alive with clinically evident disease, 6 died (3 of prostate disease 3.9{\%}). Conclusion Our results suggest that a more aggressive treatment is necessary. Local treatment intensification based on the “mixed beam” approach combining carbon ions (with its known radiobiological advantages) and photons might represent a promising strategy in high-risk prostate cancer and it will be investigated with our prospective clinical trial.",
keywords = "Carbon ions, Mix beam approach, Photons, Prostate cancer",
author = "Giulia Marvaso and Jereczek-Fossa, {Barbara A.} and Giulia Riva and Camilla Bassi and Cristiana Fodor and Delia Ciardo and Raffaella Cambria and Floriana Pansini and Dario Zerini and {De Marco}, Paolo and Federica Cattani and {De Cobelli}, Ottavio and Roberto Orecchia",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.clgc.2017.01.007",
language = "English",
volume = "15",
pages = "376--383",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - High-Risk Prostate Cancer and Radiotherapy

T2 - The Past and the Future. A Benchmark for a New Mixed Beam Radiotherapy Approach

AU - Marvaso, Giulia

AU - Jereczek-Fossa, Barbara A.

AU - Riva, Giulia

AU - Bassi, Camilla

AU - Fodor, Cristiana

AU - Ciardo, Delia

AU - Cambria, Raffaella

AU - Pansini, Floriana

AU - Zerini, Dario

AU - De Marco, Paolo

AU - Cattani, Federica

AU - De Cobelli, Ottavio

AU - Orecchia, Roberto

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Radiotherapy still remains a fundamental approach in the treatment of prostate cancer even in high-risk patients. In the past decade, dose escalation has guaranteed a better local control of disease with a great tolerance in terms of side effects. Our results constitute a benchmarking exercise for a prospective trial that involves the use of heavy particles as integration of conventional treatment with photons. Background The prognosis for patients with high-risk prostate cancer is poor. No consensus exists on the most effective treatment. The aim of this retrospective study was to identify the biochemical progression-free survival and the toxicity profile of patients with localized high-risk prostate cancer treated with external beam radiation therapy. These results will constitute a benchmark for a prospective “mixed beam” trial: a boost with carbon ions followed by a pelvic photon intensity-modulated radiotherapy (NCT02672449 [clinicaltrials.gov]). Patients and Methods We retrospectively reviewed the data of 76 patients treated in our institution with photon radiation therapy according to the inclusion criteria of the future “mixed beam” trial: cT3a and/or serum prostate-specific antigen > 20 ng/mL and/or Gleason score of 8 to 10, cN0 cM0. Toxicity, and biochemical and clinical progression-free survival were assessed. Results Seventy-six patients fulfilled our criteria. The median follow-up was 30.2 months (range, 7.2-61.1). Biochemical progression was observed in 22 patients (28.9%) after a median time of 20.2 months (range, 5-58.1) from the end of radiotherapy. Sixteen patients had clinical progression, in all the cases preceded by biochemical progression. Fifty-seven patients (75%) are alive with no evidence of disease, 13 (17.1%) are alive with clinically evident disease, 6 died (3 of prostate disease 3.9%). Conclusion Our results suggest that a more aggressive treatment is necessary. Local treatment intensification based on the “mixed beam” approach combining carbon ions (with its known radiobiological advantages) and photons might represent a promising strategy in high-risk prostate cancer and it will be investigated with our prospective clinical trial.

AB - Radiotherapy still remains a fundamental approach in the treatment of prostate cancer even in high-risk patients. In the past decade, dose escalation has guaranteed a better local control of disease with a great tolerance in terms of side effects. Our results constitute a benchmarking exercise for a prospective trial that involves the use of heavy particles as integration of conventional treatment with photons. Background The prognosis for patients with high-risk prostate cancer is poor. No consensus exists on the most effective treatment. The aim of this retrospective study was to identify the biochemical progression-free survival and the toxicity profile of patients with localized high-risk prostate cancer treated with external beam radiation therapy. These results will constitute a benchmark for a prospective “mixed beam” trial: a boost with carbon ions followed by a pelvic photon intensity-modulated radiotherapy (NCT02672449 [clinicaltrials.gov]). Patients and Methods We retrospectively reviewed the data of 76 patients treated in our institution with photon radiation therapy according to the inclusion criteria of the future “mixed beam” trial: cT3a and/or serum prostate-specific antigen > 20 ng/mL and/or Gleason score of 8 to 10, cN0 cM0. Toxicity, and biochemical and clinical progression-free survival were assessed. Results Seventy-six patients fulfilled our criteria. The median follow-up was 30.2 months (range, 7.2-61.1). Biochemical progression was observed in 22 patients (28.9%) after a median time of 20.2 months (range, 5-58.1) from the end of radiotherapy. Sixteen patients had clinical progression, in all the cases preceded by biochemical progression. Fifty-seven patients (75%) are alive with no evidence of disease, 13 (17.1%) are alive with clinically evident disease, 6 died (3 of prostate disease 3.9%). Conclusion Our results suggest that a more aggressive treatment is necessary. Local treatment intensification based on the “mixed beam” approach combining carbon ions (with its known radiobiological advantages) and photons might represent a promising strategy in high-risk prostate cancer and it will be investigated with our prospective clinical trial.

KW - Carbon ions

KW - Mix beam approach

KW - Photons

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85012932687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012932687&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2017.01.007

DO - 10.1016/j.clgc.2017.01.007

M3 - Article

AN - SCOPUS:85012932687

VL - 15

SP - 376

EP - 383

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 3

ER -